Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
Gardasil shipment pause, weak guidance, and looming Keytruda risks send investors scrambling--can Merck turn things around?
This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback